Structure (Penicillamine Capsules 210976 1)
Penicillamine Capsule
Product Images NDC 0591-4171
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Penicillamine (NDC 0591-4171). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Actavis Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Process (Penicillamine Capsules 210976 2)
This text describes the chemical abbreviations and formulas for cystine, cysteine (deprotonated), penicillamine, deprotonated penicillamine sulfhydryl, and penicillamine-cysteine mixed disulfide. It includes chemical equations showing the reactions between these compounds.*
Ndc 0591-4171-01 (Penicillamine Capsules 210976 3)
This is the description for Penicillamine Capsules USP 250 mg, a medication that comes in a child-resistant package and is usually taken by adults, according to the accompanying package outsert. The container should be kept closed and out of the reach of children. The medication is manufactured in India by Watson Pharma Private and is distributed by Tova Pharmaceuticals in North Wales, PA. However, there is some text missing from the , as there are several numbers and symbols that do not make sense when placed together.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
